Animal Vaccines Market to Surpass USD 15,275.6 Million by 2033

Animal Vaccines Market Reaches USD 9,815.7 Mn in 2026, Driven by Increasing Livestock Population and Growing Demand for Preventive Animal Healthcare

Rising Zoonotic Disease Burden and Growing Livestock Immunization Programs to Drive Animal Vaccines Market to USD 15,275.6 Million by 2033 at 6.6% CAGR – Coherent Market Insights

Global Animal Vaccines Market, by Product Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, and Recombinant Vaccines), by Application (Companion Animal, Livestock Animal, Poultry, and Aquaculture), by Distribution Channel (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at USD 9,815.7 Mn in 2026, and is expected to exhibit a CAGR of 6.6% during the forecast period (2026-2033).

Recent advancements in technology and improved understanding of pathogenicity, immunology and epidemiology, and introduction of genetic engineering have opened new opportunities for preventing infectious diseases such as rabies, Lyme disease, cancer, and canine distemper. For instance, in December 2018, EvviVax, a biotechnology company, aims to offer novel therapeutic avenues to pet cancer patients, developed a novel vaccine called Tel-eVax that targets Telomerase, the enzyme that maintains telomeres and prevents them from shortening during cell division. Moreover, Tel-eVax has shown efficacy for canine B-cell Lymphoma in three trials and is currently being evaluated in other tumor types.

Browse 28 Market Data Tables and 78 Figures spread through 180 Pages and in-depth TOC on Global Animal Vaccines Market, by Product Type (Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines, and Recombinant Vaccines), by Application (Companion Animal, Livestock Animal, Poultry, and Aquaculture), by Distribution Channel (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).

To know the latest trends and insights prevalent in the global animal vaccines market, click the link below:

https://www.coherentmarketinsights.com/market-insight/animal-vaccines-market-4989

Viral outbreak in livestock population such as nipah virus, swine flu, canine influenza, bird flu, and avian influenza are expected to drive growth of the veterinary vaccine market over the forecast period. Nipah virus outbreak found in equine veterinarians in 2018 has influenced scientists to create vaccine, for global concerns. Furthermore, in 2018, the World Health Organization listed Nipah infection as a public health risk with epidemic potential.

Key News

• In February 2025, Boehringer Ingelheim, pharmaceutical company launched VAXXITEK HVT+IBD+H5, a trivalent poultry vaccine targeting H5 avian influenza, Marek’s disease, and infectious bursal disease. The hatchery-administered vaccine uses COBRA technology to provide broad cross-clade protection against prevalent H5 strains. Initially launched in Egypt, it supports poultry farmers in strengthening flock health, reducing disease risk, and improving sustainable poultry production.
• In January 2026, HIPRA India Private Limited, pharmaceutical company and Elanco Animal Health, leader in farm and companion animal health have partnered to introduce two avian metapneumovirus vaccines, RESPIVAC aMPV and HIPRAVIAR TRT, to the U.S. poultry market. The vaccines aim to help producers manage costly respiratory disease affecting turkeys, broilers, layers, and breeders. HIPRA said 60–80% of commercial turkey flocks nationwide are impacted, and field trials under emergency import licensing showed improved outcomes among vaccinated birds in 2025. (Source: HIPRA India Private Limited)
• At BioAsia 2026, Telangana announced major life sciences investments, including Vaksindo Animal Health’s BSL-3 vaccine manufacturing facility in Genome Valley for poultry, cattle, swine, and aquaculture. The state also attracted GCC expansions from Tredence and Opella Healthcare, along with Rx Propellant’s ₹1,000 crore advanced laboratory campus. These projects are expected to strengthen Hyderabad’s biotechnology ecosystem, vaccine manufacturing capacity, and innovation-led healthcare infrastructure and support future animal health research capabilities nationwide.
• In July 2026, ECO Animal Health commercially launched ECOVAXXIN MS across the European Union in July 2026. The vaccine targets Mycoplasma synoviae in layer and breeder chickens and is designed to reduce air-sac lesions, foot-pad lesions, and egg production losses. The launch covers EU markets representing over 220 million layer birds annually.

Key Takeaways of the Global Animal Vaccines Market

• The global animal vaccines market is expected to exhibit a CAGR of 6.6% over the forecast period (2026-2033). North America is expected to account for major market share over the forecast period (2026-2033), owing rising number of product launches and approvals. For instance, in November 2017, AgriLabs, a U.S. based biopharmaceutical company, received the U.S. Department of Agriculture (U.S.DoA) approval of the first ever DNA vaccine licensed for chickens. The approval also represents the first for AgriLabs' ExactVac DNA technology with ENABL adjuvant, the first DNA vaccine approved for influenza for veterinary use, and among the first DNA vaccines approved in the U.S. for food animals.
• Attenuated Live Vaccines segment is expected to witness fastest growth in the global animal vaccines market over the forecast period. The growth of the segment is attributed to rapid research and development of attenuated live vaccines. For instance, according to the World Health Organization’s 2018 estimation, several modified-live (ML) rabies virus vaccine candidates such as SAD (Street Alabama Dufferin)-Bern vaccine, Vnukovo-32, and others have been developed for the oral immunization of animals in the past 35 years
• Some of the major players operating in the global animal vaccines market include Merck & Co., Inc., Boehringer Ingelheim International GmbH., Zoetis Inc., Elanco Animal Health Incorporated, Ceva, HIPRA, Romvac Company Sa, Biovac, Vaxxinova International BV, and Biogénesis Bagó